Alzchem Group Ag · XETR:ACT
Alzchem — Q2 2023 Earnings Presentation
36 slides from Alzchem's earnings presentation, Aug 3, 2023
Slide 1: Agile Science Pure Results
AGILE SCIENCE PURE RESULTS
Slide 2: Andreas Niedermaier, CEO and Dr. Georg Weichselbaumer, CSO
ANDREAS NIEDERMAIER, CEO , DR. GEORG WEICHSELBAUMER, CSO 2023 August 3, 2023
Slide 3: Disclaimer
DISCLAIMER CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available info
Slide 4: Agenda — Analyst Presentation Q2 2023
AGENDA — ANALYST PRESENTATION Q2 2023 Executive Summary
Slide 5: Highlights
HIGHLIGHTS Sales & EBITDA above prior year & guidance confirmed Sales and EBITDA Substantial growth in Operating cash flow above prior year with the human nutrition and free cash flow different impact from market strongly positive and segments much higher compared to last year . Guidance confirmed f
Slide 6: Verbund System — Fully Integrated Business Model
© Alzch2m Group AG / August 2023 “VERBUND” SYSTEM — FULLY INTEGRATED BUSINESS MODEL Ability to adapt production to meet changing end market needs CALCIUM 6 \ CYANAMIDE nTRALz* 1 RENEWABLE nd Infrastructure ENE Wan CARBON ENERGY AN
Slide 7: Verbund System — Fully Integrated Business Model
© Alzchem Group AG / August 2023 “VERBUND” SYSTEM — FULLY INTEGRATED BUSINESS MODEL Health & Nutrition AE Creapure” 7 088 Creapure’ LIVA DUR 688 Creavitalis’ Premium brand for creatine monohydrate as a food supplement in sports nutrition Dietary supplement with pure creatine Creatine for health and
Slide 8: Creatine in Sport, Fitness, Health & Food
© Alzch2m Group AG / August 2023 KREATIN IN SPORT, FITNESS, HEALTH & FOOD Creatine boosts body energy in many areas 008 Creapure’ OUR MARKETS Sport Fitness Health Food B2B G@grleleace B2Cc 688 Creavitalis’ WS
Slide 9: Creavitalis
688 Creavitalis’ I X Creatine for health & food applications (ny WHY CREAVITALIS® * Tailor made creatine product for health and food applications * — Specific marketing to approach new markets * Micronization and tigh analytical control to respond to consumer expectations * Scientific studies to sup
Slide 10: Financial Overview
FINANCIAL OVERVIEW Positive development in a challenging environment SALES (in M€) EBITDA (in M€) EBITDA margin (in %) Earnings per Share (in €) epi Substantial gre 1 in the human nutrition market; continued s armaceutical inc and in the moti declinir ntration on high-r in volumes in the 2nd quarter
Slide 11: Agenda — Business and financial details
AGENDA — ANALYST PRESENTATION Q2 2023 ll. Business and financial details
Slide 12: Basics & Intermediates
NITRALZ® CBerlka’ iG al BASICS & INTERMEDIATES The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of
Slide 13: Basics & Intermediates Segment (in M€)
BASICS & INTERMEDIATES SEGMENT (in M€) Volume reductions but increased EBITDA SALES ANALYSIS 57.9 46.0 Q2. 03 Q4- QI Q2 3 4 QI QR 2021 2021 2021 2022 2022 2022 2022 2023 2023 Slight relief ning EBITDA-Margin of 5,2 % in Q2. Q3 -Q4) QI QZ QB 4 QI QR 1-6 1-6 2021 2021 2021 2022 2022 2022 2022 2023 202
Slide 14: Specialty Chemicals
a Pa ( CREAMINO Drmex' Bioselect? DYHARD #88 Creapure® SPECIALTY CHEMICALS The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.
Slide 15: Specialty Chemicals Segment (in M€)
SPECIALTY CHEMICALS SEGMENT (in me) Sales increase in first half of 2023, lower volumes affect EBITDA SALES ANALYSIS Q2. 03 Q4- QI Q2 3 4 QI QR 2021 2021 2021 2022 2022 2022 2022 2023 2023 at one 9 in Q2/ Deman EBITDA-A Q2. 93 24) Qi QZ. QB 4 QI QR 1-6 1-6 1-6 1-6 2021 2021 2021 2022 2022 2022 2022
Slide 16: Other & Holding
The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers. Gti. “a OTHER & HOLDING
Slide 17: Other & Holding Segment (in M€)
OTHER & HOLDING SEGMENT (in mé€) Development of services in line with 2022 and cost bases Q2. Q3_ Q4- QI QZ QB 4 QI 2 2021 2021 2021 2022 2022 2022 2022 2023 2023 COMMENTS Q2. Q3_ Q4- QI QZ QB 4 QI 2 2021 2021 2021 2022 2022 2022 2022 2023 2023
Slide 18: Balance Sheet (in M€)
BALANCE SHEET (in mé€) Stable balance sheet development with improved equity ratio Other non-current assets Deferred taxes for pension provision Inventories Trade receivables Other current assets 31.12.2022 30.06.2023 slightly in op ainly stable id no changes in payrr 419.2 ME, nt and n e directions
Slide 19: Cashflow (in M€)
CASHFLOW (in Mé€) Strong operating and free cashflow; reduction of short-term financing rom inv Y tment C arked ructuring of financing policy in first half yea e wn in investing in capacity loans from current to non-current (30.0 Mé). Additional reducti F y of th the c 5 rm financing lir
Slide 20: Implementing Operating Targets
IMPLEMENTING OPERATING TARGETS Focus on the key growth drivers and sustainability IMPROVEMENT ~ GROWTH 4, SUSTAINABILITY * Raw material price increases at * Volume growth and full utilization of [4 * Vision 0 accidents and O waste least passed on to the market realized capex (Creapure®, : as a ' * I
Slide 21: Outlook 2023 (in M€)
OUTLOOK 2023 (in Mé€) Outlook from 2022 confirmed, different development in ranges COMMENTS * Outlook 2023 from annual statements 2 confirmed c p sales are exp d to end up at the lower end of the forecasted range slight growth up to 590.0 ME EBITDA is ex, range slight growth up to 70.0 ME 2022 FC 20
Slide 22: Financial Calendar
FINANCIAL CALENDAR Upcoming dates* “subject to change SEP 18 SEP 20 OCT 19 OCT 26 NOV 15 NOV 27 — 29 2023 2023 2023 2023 2023 2023 WS Baader Investment Conference 2023 Berenberg and Goldman Sachs German Corporate Conference 2023 Warburg "Klein aber fein" Konferenz 2023 Quarterly Statement 3rd Quarte
Slide 23: Investor Relations
alzchem group Investor Relations T +49 8621 86-2888 F +49 8621 86-502888 ir@alzchem.com
Slide 24: Agenda — Analyst Presentation Q2 2023
AGENDA — ANALYST PRESENTATION Q2 2023
Slide 25: Balance Sheet
© Alzchem Group AG / August 2023 BALANCE SHEET Alzchem Group ALZCHEM GROUP (IN Té) 31122022 30,06.2023 Deviation ‘ALZCHEM GROUP (IN TE) 3112.2022 30.06.2023 Deviation Intangible assets 2,954 3,038 a4 (28% Share capital 101,763 101,763 Tangible assets 181526 176826 4701 -2.6% RETAINED EARNINGS (+) /
Slide 26: Pension Accounting (IFRS)
PENSION ACCOUNTING (IFRS) Alzchem Group (M€) IN FINANCIAL PENSION SERVICE NET INTEREST PENSION STATEMENT PROVISION costs PAYMENTS 31.12.2022 FINAN RESULT BALANCE SHEET P&L CASHFLOW, Adjustment of market interest rate from f > 3.6%; increasing impact on provision Stable development of expected pensio
Slide 27: Income Statement
© Alzchem Group AG / August 2023 INCOME STATEMENT Alzchem Group ALZCHEM GROUP (NTE) vor zo nome moma nars aos ams noms _——_—eation(Qi Revenue 129395 140,435 139,193 133.200 150,432 126,599, 13,836 -10% Increase (+) / Decrease (-) ininventories of finished goods and workin progress 14144 14467-1959 4
Slide 28: Income Statement
© Alzchem Group AG / August 2023 INCOME STATEMENT Alzchem Group ALZCHEM GROUP (IN TE) a os Deviation (QoQ) a Deviation (YoY) Revenue 140,435 126,599, ~13,836 “2.9% 269,830 277,031 7201 27% Increase (+) / Decrease (-) in inventories of finished goods and work in progress 14,467 9105 “5361 37.1% 23,61
Slide 29: Cashflow Statement
© Alzchem Group AG / August 2023 CASHFLOW STATEMENT Alzchem Group Q2 Qa 1-6 1-6 CASHFLOW (IN Me} 2022 2023 2022 2023 ‘Consolidated earnings before taxes 13,258 9,982 24,601 20,747 Depreciation on fixed and intangible assets 6299 6335 12,604 12,655 Decrease in pension provisions -364 -403 -878 -967 L
Slide 30: Segment Overview by Quarter
SEGMENT OVERVIEW BY QUARTER X Alzchem Group v SALES SALES Q3 O4 Deviation PY (22) Te Te Te Basics & Intermediates 11,889 Specialty Chemicals -3,042 Other and Holding 1,095 Group Consolidation Alzchem Group, 104,321 11,000 11,052 129,395 140,435 139,193 133,200 150,432 126,599 EBITDA Qi Q2 fer} O4 De
Slide 31: Executive Team
EXECUTIVE TEAM Alzchem Group AG me n- om : fem > DR. GEORG WEICHSELBAUMER CSO BEI ALZCHEM SEIT 2012 RESSORTVERANTWORTUNG. Marketing, Vertrieb, Innovationsmanagement & Verfahrensentwicklung, F&E, Produktsicherheit /-zulassung ANDREAS NIEDERMAIER CEO BEI ALZCHEM SEIT 1999 RESSORTVERANTWORTUNG Finanzen
Slide 32: Alzchem Group Locations
ALZCHEM GROUP LOCATIONS Production sites and sales companies COVENTRY (UK) Group AG / August 2023 SHANGHAI (CN) Pa ATLANTA (USA) © Alzchem
Slide 33: Verbund — Fully Integrated Business Model
© Alzchem Group AG / August 2023 “VERBUND” — FULLY INTEGRATED BUSINESS MODEL ANN Benefits of the “Verbund” system approach (ay O Segment Specialty Chemicals BENEFITS OF “VERBUND” O Segment . oo. Basics & Inter- ¢ Full control of product quality and specifications mediates * Lower costs * Higher fina
Slide 34: Our Products and Markets
© Alzchem Group AG / August 2023 OUR PRODUCTS AND MARKETS ANN Successful with proven and new products in various industries (ay MAIN PRODUCTS DESCRIPTION END-MARKETS CREAMINO’ Anutritional additive for poultry and pigs Feed additive Creapure’ Creapure®, premium brand for creatine monohydrate as ingr
Slide 35: Our Products and Markets
© Alzchem Group AG / August 2023 OUR PRODUCTS AND MARKETS Successful with proven and new products in various industries n w = a < n ae a ta co Wi [= e OTHER & HOLDING WS MAIN PRODUCTS DESCRIPTION END-MARKETS an Calcium carbide-based mixtures for hot metal desulphurization Steel industry al Guanidine
Slide 36: Key Share Data
© Alzchem Group AG / August 2023 KEY SHARE DATA Share Details as of August 1, 2023 “MS SHARES OUTSTANDING. LAST CLOSING PRICE MARKET CAPITALIZATION TICKER WKN ISIN LISTING DESIGNATED SPONSOR SHAREHOLDER 10,176,335 STRUCTURE LIVIA Corporate EUR 18.95, Development SE 25.13% EUR 192.8m Free float AT.08